Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.

ABSTRACT:

Background

Deregulation of cell-cycle pathway is ubiquitously observed in human papillomavirus negative (HPV^neg) head and neck squamous cell carcinoma (HNSCC). Despite being an attractive target, CDK4/6 inhibition using palbociclib showed modest or conflicting results as monotherapy or in combination with platinum-based chemotherapy or cetuximab in HPV^neg HNSCC. Thus, innovative agents to augment the efficacy of palbociclib in HPV^neg HNSCC would be welcomed.

Methods

A collection of 162 FDA-approved and investigational agents was screened in combinatorial matrix format, and top combinations were validated in a broader panel of HPV^neg HNSCC cell lines. Transcriptional profiling was conducted to explore the molecular mechanisms of dru

SUBMITTER: Gu Z 

PROVIDER: S-EPMC9097351 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature